TAS-102 and Bevacizumab as third line chemotherapy for colorectal cancer. Phase 2 trial

Phase 2

• Conditions: metastatic colorectal cancer

• Registration Number: JPRN-UMIN000022438
• Lead Sponsor: Teikyo University Chiba Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-08-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 31

Inclusion Criteria

Not provided

Exclusion Criteria

1)contraindications for TAS-102 and BEvacizumab 2)previously received chemotherapy with TAS-102 3)severe drug allergy 4)pregnant woman or Possibility of the pregnant woman. male patient who hoping partner's pregnancy. 5)patient who has important clinical complications(symptomatic unstable ischemic heart disease, arrhythmia, acute myocardial infarction within 6 months, liver cirrhosis, renal failure, active gastrointestinal ulcer, ileus, uncontrolled diabetes, uncontrolled hypertension, etc.) 6)other active malignancies 7)have pleural effusion and ascitic fluid with the treatment 8)Comorbidity or history of heart failure 9)gastrointestinal ulcer or bleeding 10)previous hemoptysis 11)Peritoneal metastases at image 12)Clinical or radiological evidence of CNS metastases 13)Current or previous (within the last 6 months) history of GI perforation 14)Patient with interstitial pneumonia or lung fibrosis confirmed in imaging study 15)ongoing treatment with anticoagulant 16)Synchronous or metachronous multiple malignancy within the last 5 year disease free interval 17)Under coutinuous steroid administration 18)dicision of unsuitable for this study by the investigator

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
progression free survival

Secondary Outcome Measures

Name	Time	Method
Time to Treatment Failure, response rate , overall survival